Top

Published in:

Open Access 09-04-2024 | Vulgar Psoriasis | Review

Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities

Authors: Luca Potestio, Nello Tommasino, Giuseppe Lauletta, Fabrizio Martora, Matteo Megna

Published in: Dermatology and Therapy | Issue 4/2024

Abstract

Psoriasis is now considered a systemic disease, and several comorbidities have been described such as cardiovascular diseases, neurologic and psychiatric disorders, chronic inflammatory bowel disease, psoriatic arthritis, etc. Regarding cardiovascular comorbidities, major adverse cardiovascular events have been reported in psoriasis patients by multiple epidemiologic studies. Moreover, smoking, obesity, metabolic syndrome, hypertension, dyslipidemia, diabetes and reduced physical activity are associated with psoriasis, increasing cardiovascular risk. Consequently, several aspects should be considered when making the treatment decision. The aim of this review manuscript was to investigate the effectiveness and safety of biologic drugs acting on molecular mechanisms involved in the pathogenesis of psoriasis in preventing cardiovascular complications.

Boehncke WH, Schön MP. Psoriasis. Lancet (London, England). 2015;386(9997):983–94. https://doi.org/10.1016/S0140-6736(14)61909-7.CrossRefPubMed

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet (London, England). 2007;370(9583):263–71. https://doi.org/10.1016/S0140-6736(07)61128-3.CrossRefPubMed

Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20184347.CrossRefPubMedPubMedCentral

McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med. 1973;288(17):912.CrossRefPubMed

Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat. 2005;16(5–6):319–23. https://doi.org/10.1080/09546630500335977.CrossRef

Masson W, Galimberti ML, Anselmi CL, Cagide A, Galimberti RL. Coronary artery disease in patients with psoriasis. Medicina (B Aires). 2013;73(5):423–7.PubMed

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41. https://doi.org/10.1001/jama.296.14.1735.CrossRefPubMed

Kimball AB, Guerin A, Latremouille-Viau D, et al. Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis. Am J Med. 2010;123(4):350–7. https://doi.org/10.1016/j.amjmed.2009.08.022.CrossRefPubMed

Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31(8):1000–6. https://doi.org/10.1093/eurheartj/ehp567.CrossRefPubMed

10.

Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017–33. https://doi.org/10.1007/s12325-020-01346-6.CrossRefPubMedPubMedCentral

11.

Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–7. https://doi.org/10.1111/jdv.12106.CrossRefPubMed

12.

Fernández-Torres RM, Paradela S, Fonseca E. Long-term response to etanercept monotherapy in moderate to severe psoriasis: assessment in daily practice by the maintenance of low values of PASI and BSA. J Dermatol Treat. 2014;25(1):54–6. https://doi.org/10.3109/09546634.2012.755254.CrossRef

13.

Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venereol. 2022;157(Suppl. 1 to No. 1):1–78. https://doi.org/10.23736/S2784-8671.21.07132-2.CrossRef

14.

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6. https://doi.org/10.1111/j.1365-2230.1994.tb01167.x.CrossRefPubMed

15.

Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris—part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–98. https://doi.org/10.1111/jdv.16915.CrossRefPubMed

16.

Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of Psoriasis vulgaris—part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. https://doi.org/10.1111/jdv.16926.CrossRefPubMed

17.

Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22:1–17 (Published online February).

18.

Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22:1–16 (Published online February).

19.

Megna M, Potestio L, Battista T, et al. Immune response to COVID-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022. https://doi.org/10.1111/ced.15395.CrossRefPubMedPubMedCentral

20.

Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–3. https://doi.org/10.1111/jocd.15414.CrossRefPubMed

21.

Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after Moderna mRNA-1273 vaccine: a case series. Dermatol Ther. 2022;35(2): e15225. https://doi.org/10.1111/dth.15225.CrossRefPubMed

22.

Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023. https://doi.org/10.1080/13543784.2023.2219387.CrossRefPubMed

23.

Giardullo L, Corrado A, Maruotti N, Cici D, Mansueto N, Cantatore FP. Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases. Int J Immunopathol Pharmacol. 2021;35:20587384211015030. https://doi.org/10.1177/20587384211015034.CrossRef

24.

Kiełbowski K, Bakinowska E, Ostrowski P, et al. The role of adipokines in the pathogenesis of psoriasis. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24076390.CrossRefPubMedPubMedCentral

25.

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20061475.CrossRefPubMedPubMedCentral

26.

Zhu KJ, Zhang C, Li M, Zhu CY, Shi G, Fan YM. Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol. 2013;38(5):478–83. https://doi.org/10.1111/ced.12171.CrossRefPubMed

27.

Kochumon S, Hasan A, Al-Rashed F, et al. Increased adipose tissue expression of IL-23 associates with inflammatory markers in people with high LDL cholesterol. Cells. 2022. https://doi.org/10.3390/cells11193072.CrossRefPubMedPubMedCentral

28.

Shibata S, Tada Y, Hau CS, et al. Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from γδ-T cells. Nat Commun. 2015;6:7687. https://doi.org/10.1038/ncomms8687.CrossRefPubMed

29.

Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007;157(6):1249–51. https://doi.org/10.1111/j.1365-2133.2007.08190.x.CrossRefPubMed

30.

Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med. 2009;206(1):249–58. https://doi.org/10.1084/jem.20080129.CrossRefPubMedPubMedCentral

31.

Smekal A, Vaclavik J. Adipokines and cardiovascular disease: a comprehensive review. Biomed Pap Med Fac Univ Palacky Olomouc Czechoslov. 2017;161(1):31–40. https://doi.org/10.5507/bp.2017.002.CrossRef

32.

Wu JJ, Poon KYT. Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both. J Drugs Dermatol. 2014;13(8):932–4.PubMed

33.

Hjuler KF, Bøttcher M, Vestergaard C, Bøtker HE, Iversen L, Kragballe K. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA Dermatol. 2016;152(10):1114–21. https://doi.org/10.1001/jamadermatol.2016.1984.CrossRefPubMed

34.

Olejniczak-Staruch I, Narbutt J, Ceryn J, et al. AntiTNF-alpha therapy normalizes levels of lipids and adipokines in psoriatic patients in the real-life settings. Sci Rep. 2021;11(1):9289. https://doi.org/10.1038/s41598-021-88552-6.CrossRefPubMedPubMedCentral

35.

Kim J, Tomalin L, Lee J, et al. Reduction of inflammatory and cardiovascular proteins in the blood of patients with psoriasis: differential responses between tofacitinib and etanercept after 4 weeks of treatment. J Investig Dermatol. 2018;138(2):273–81. https://doi.org/10.1016/j.jid.2017.08.040.CrossRefPubMed

36.

Di Minno MND, Iervolino S, Zincarelli C, et al. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database. Expert Opin Drug Saf. 2015;14(12):1905–13. https://doi.org/10.1517/14740338.2015.1111870.CrossRefPubMed

37.

Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study. J Dermatol. 2017;44(4):363–9. https://doi.org/10.1111/1346-8138.13661.CrossRefPubMed

38.

Holzer G, Hoke M, Sabeti-Sandor S, et al. Disparate effects of adalimumab and fumaric acid esters on cardiovascular risk factors in psoriasis patients: results from a prospective, randomized, observer-blinded head-to-head trial. J Eur Acad Dermatol Venereol. 2021;35(2):441–9. https://doi.org/10.1111/jdv.16635.CrossRefPubMed

39.

Heathfield SK, Parker B, Zeef LAH, Bruce IN, Alexander MY. Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol. 2013;31(2):225–33.PubMed

40.

Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. https://doi.org/10.1016/j.jaad.2018.06.057.CrossRefPubMed

41.

Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35–55. https://doi.org/10.1007/s40259-022-00569-z.CrossRefPubMedPubMedCentral

42.

Famenini S, Sako EY, Wu JJ. Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors. Am J Clin Dermatol. 2014;15(1):45–50. https://doi.org/10.1007/s40257-013-0052-6.CrossRefPubMed

43.

Koschitzky M, Navrazhina K, Garshick MS, et al. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris. Exp Dermatol. 2022;31(9):1341–51. https://doi.org/10.1111/exd.14582.CrossRefPubMedPubMedCentral

44.

Onsun N, Akaslan TÇ, Sallahoglu K, Gülcan AS, Bulut H, Yabacı A. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study. J Dermatol Treat. 2022;33(3):1727–32. https://doi.org/10.1080/09546634.2021.1901845.CrossRef

45.

Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol. 2020;140(1):85-93.e2. https://doi.org/10.1016/j.jid.2019.07.679.CrossRefPubMed

46.

Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Investig Dermatol. 2020;140(9):1784-1793.e2. https://doi.org/10.1016/j.jid.2020.01.025.CrossRefPubMed

47.

von Stebut E, Reich K, Thaçi D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Investig Dermatol. 2019;139(5):1054–62. https://doi.org/10.1016/j.jid.2018.10.042.CrossRef

48.

Lockshin B, Balagula Y, Merola JF. Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. J Am Acad Dermatol. 2018;79(2):345–52. https://doi.org/10.1016/j.jaad.2018.02.040.CrossRefPubMed

49.

Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018;79(1):104-109.e8. https://doi.org/10.1016/j.jaad.2018.02.074.CrossRefPubMed

50.

Rungapiromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft DM. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017;176(4):890–901. https://doi.org/10.1111/bjd.14964.CrossRefPubMedPubMedCentral

51.

Griffiths CEM, Gooderham M, Colombel JF, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatol Ther (Heidelb). 2022;12(6):1431–46. https://doi.org/10.1007/s13555-022-00743-9.CrossRefPubMed

52.

Hatipoglu D, Tanski C, Hachamovitch R, Legha S, Moudgil R. Ixekizumab-induced cardiac sarcoidosis: a case report. CJC open. 2021;3(1):118–20. https://doi.org/10.1016/j.cjco.2020.08.012.CrossRefPubMed

53.

van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82(4):515–26. https://doi.org/10.1136/ard-2022-223595.CrossRefPubMed

54.

Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1243843. https://doi.org/10.3389/fmed.2023.1243843.CrossRef

55.

Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckland, NZ). 2022;12:205–12. https://doi.org/10.2147/PTT.S372262.CrossRef

56.

Strober B, Coates LC, Lebwohl MG, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47(1):39–57. https://doi.org/10.1007/s40264-023-01361-w.CrossRefPubMed

57.

Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019;20(7):863–72. https://doi.org/10.1080/14656566.2019.1583207.CrossRefPubMed

58.

Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676–84. https://doi.org/10.1111/jdv.15653.CrossRefPubMedPubMedCentral

59.

Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–75. https://doi.org/10.1111/bjd.20818.CrossRefPubMed

60.

Bissonnette R, Fernández-Peñas P, Puig L, Mendelsohn AM, Rozzo SJ, Menter A. Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. J Eur Acad Dermatol Venereol. 2020;34(1):e21–4. https://doi.org/10.1111/jdv.15866.CrossRefPubMed

61.

Egeberg A, Jullien D, GaarnDuJardin K, Thaçi D. Five-year safety of tildrakizumab in patients with moderate-to-severe psoriasis from two phase 3 trials (reSURFACE 1 and reSURFACE 2): number needed to harm for occurrence of adverse events of special interest. J Dermatol Treat. 2023;34(1):2220447. https://doi.org/10.1080/09546634.2023.2220447.CrossRef

62.

Cacciapuoti S, Megna M, Salza E, Potestio L, Caiazzo G. The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study. J Dermatol Treat. 2024;35(1):2291323. https://doi.org/10.1080/09546634.2023.2291323.CrossRef

63.

Gelfand JM, Shin DB, Armstrong AW, et al. Association of apremilast with vascular inflammation and cardiometabolic function in patients with psoriasis: the VIP-A phase 4, open-label, nonrandomized clinical trial. JAMA Dermatol. 2022;158(12):1394–403. https://doi.org/10.1001/jamadermatol.2022.3862.CrossRefPubMedPubMedCentral

64.

Pina Vegas L, Le Corvoisier P, Penso L, Paul M, Sbidian E, Claudepierre P. Risk of major adverse cardiovascular events in patients initiating biologics/apremilast for psoriatic arthritis: a nationwide cohort study. Rheumatology (Oxford). 2022;61(4):1589–99. https://doi.org/10.1093/rheumatology/keab522.CrossRefPubMed

65.

Elnabawi YA, Oikonomou EK, Dey AK, et al. Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular Fat Attenuation Index. JAMA Cardiol. 2019;4(9):885–91. https://doi.org/10.1001/jamacardio.2019.2589.CrossRefPubMedPubMedCentral

66.

Megna M, Potestio L, Ruggiero A, et al. JAK inhibitors in psoriatic disease. Clin Cosmet Investig Dermatol. 2023;16:3129–45. https://doi.org/10.2147/CCID.S433367.CrossRefPubMedPubMedCentral

67.

Jin JQ, Spencer RK, Reddy V, Bhutani T, Liao W. Clinical utility of deucravacitinib for the management of moderate to severe plaque psoriasis. Ther Clin Risk Manag. 2023;19:413–23. https://doi.org/10.2147/TCRM.S388324.CrossRefPubMedPubMedCentral

68.

Chimalakonda A, Singhal S, Darbenzio R, et al. Lack of electrocardiographic effects of deucravacitinib in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(4):442–53. https://doi.org/10.1002/cpdd.1056.CrossRefPubMedPubMedCentral

69.

Flammer AJ, Ruschitzka F. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J. 2012;33(16):1989–91. https://doi.org/10.1093/eurheartj/ehr425.CrossRefPubMed

70.

Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–9. https://doi.org/10.1136/annrheumdis-2014-206624.CrossRefPubMed

71.

Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21–8. https://doi.org/10.1016/j.clindermatol.2017.09.005.CrossRefPubMed

72.

Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022. https://doi.org/10.1080/14712598.2022.2113872.CrossRefPubMed

Title: Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Authors: Luca Potestio
Nello Tommasino
Giuseppe Lauletta
Fabrizio Martora
Matteo Megna
Publication date: 09-04-2024
Publisher: Springer Healthcare
Keywords: Vulgar Psoriasis
Ustekinumab
Published in: Dermatology and Therapy / Issue 4/2024
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-024-01152-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2024

Novel Topical Treatments for Itch

Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries

Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study”

Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment

Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study

Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage